A PHASE I, OPEN LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF TTI-622 (PF-07901801), A SINGLE AGENT IN JAPANESE PARTICIPANTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES

Pfizer Japan Inc.0 个研究点目标入组 7 人开始时间: 2022年11月2日最近更新: 2024年11月15日

试验速览

暂无简介。

•Inclusion Criteria:
•Relapsed or refractory lymphoma (Hodgkin's or non-Hodgkin's) or multiple myeloma
•Disease must have progressed with standard anticancer therapies
•measurable disease
•Capable of giving signed informed consent
•Eastern cooperative oncology group performance status 0 or 1
•Adequate organ functions

•Exclusion Criteria:
•Known, current central nervous system or interstitial lung disease involvement
•History of hemolytic anemia or positive direct antiglobulin test or active bleeding disorder
•Chronic use of systemic corticosteroids of more than 20 mg/day of prednisone or equivalent
•Significant cardiovascular disease
•Other significant medical condition unrelated to the primary malignancy
•Radiation therapy within 14 days of study treatment administration
•Hematopoietic stem cell transplant within 90 days before the planned start of study treatment
•Antiplatelet/anticoagulant agents within 14 days before planned start of study treatment
•Patients sustaining major surgery at least 4 weeks prior to study enrollment
•Use of any investigational agent or any anticancer drug within 14 days before planned start of study treatment
•Prior anti-CD47 and anti-Signal Regulatory Protein alpha therapy
•Active, uncontrolled bacterial, fungal, or viral infection
•Investigator site staff directly involved in the conduct of the study and their family members

Number of Participants with Dose Limiting Toxicity (DLT) in lymphoma

时间窗: up to 21 days

Number of participants with DLTs

未报告次要终点

发起方